Rare disease diagnosis technology developer Centogene is gearing up for an IPO having spun out from Rostock in 2006 and raised $28.5m of equity funding in 2017.
Centogene, a Germany-based rare disease diagnosis technology spinout from University of Rostock, is considering going public in an initial public offering on the Nasdaq stock exchange, Reuters reported on Friday.
The transaction could reportedly take place as soon as the second or third quarter of 2019.
Founded in 2006, Centogene has created a diagnostics system billed as the world’s largest database of genetic mutations for rare inherited diseases such as polycystic kidney disease and spastic paraplegia.
The…
